FTRE (Fortrea Holdings) Valuation Rank


FTRE Fortrea Holdings Inc FTRE
66 GF Score
Price $17.64
GF Value $18.26
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Fortrea Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Fortrea Holdings Valuation Rank Related Terms

FTRE
66GF Score
Fortrea Holdings Inc FTRE
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fortrea Holdings (FTRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued. The current stock price of $17.64 is trading 3.4% below its estimated GF Value™ of $18.26. GuruFocus considers Fortrea Holdings to be Fairly Valued.

Key valuation signals for FTRE:

  • Valuation Rank:
  • GF Value™: $18.26 vs. price of $17.64 (3.4% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortrea Holdings Business Description

Other Exchanges K67:Germany
Address 8 Moore Drive, Durham, NC, USA, 27713
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score

Get the complete analysis for FTRE

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.64
Price
$18.26
GF Value